KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

(Medage today) – Treatment with Adagrasib (Krazati) has considerably improved progression -free survival (PFS) in patients treated previously with lung cancer not with small Mras G12C cells (NSCLC) compared to doctaxel, phase III Krystal …